Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532486) titled 'A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis' on April 8.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Condition:
Psoriasis
Intervention:
Drug: Guselkumab
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: July 10, 2024
Target Sample Size...